Australia - inglese - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - donepezil hydrochloride, quantity: 5 mg - tablet, film coated - excipient ingredients: hyprolose; lactose monohydrate; microcrystalline cellulose; magnesium stearate; maize starch; hypromellose; macrogol 400; titanium dioxide - arazil (donepezil hydrochloride) is indicated for the treatment of mild, moderate and severe alzheimer?s disease.

Regno Unito - inglese - MHRA (Medicines & Healthcare Products Regulatory Agency)

takeda uk ltd - azilsartan medoxomil - tablet - 20mg

Regno Unito - inglese - MHRA (Medicines & Healthcare Products Regulatory Agency)

takeda uk ltd - azilsartan medoxomil - tablet - 40mg

Regno Unito - inglese - MHRA (Medicines & Healthcare Products Regulatory Agency)

takeda uk ltd - azilsartan medoxomil - tablet - 80mg

Canada - inglese - Health Canada

bausch health, canada inc. - azilsartan medoxomil (azilsartan medoxomil potassium) - tablet - 40mg - azilsartan medoxomil (azilsartan medoxomil potassium) 40mg - angiotensin ii receptor antagonists

Canada - inglese - Health Canada

bausch health, canada inc. - azilsartan medoxomil (azilsartan medoxomil potassium) - tablet - 80mg - azilsartan medoxomil (azilsartan medoxomil potassium) 80mg - angiotensin ii receptor antagonists

Australia - inglese - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - rasagiline mesilate, quantity: 1.56 mg (equivalent: rasagiline, qty 1 mg) - tablet - excipient ingredients: stearic acid; purified talc; mannitol; colloidal anhydrous silica; maize starch; pregelatinised maize starch - azilect is indicated for the symptomatic treatment of idiopathic parkinson?s disease (pd) as monotherapy and as adjunct therapy to dopamine agonists or to levodopa.

Stati Uniti - inglese - NLM (National Library of Medicine)

remedyrepack inc. - lamotrigine (unii: u3h27498ks) (lamotrigine - unii:u3h27498ks) - lamotrigine 50 mg - lamotrigine extended-release is indicated as adjunctive therapy for primary generalized tonic-clonic (pgtc) seizures and partial-onset seizures with or without secondary generalization in patients aged 13 years and older. lamotrigine extended-release is indicated for conversion to monotherapy in patients aged 13 years and older with partial-onset seizures who are receiving treatment with a single antiepileptic drug (aed). safety and effectiveness of lamotrigine extended-release have not been established (1) as initial monotherapy or (2) for simultaneous conversion to monotherapy from two or more concomitant aeds. safety and effectiveness of lamotrigine extended-release for use in patients younger than 13 years have not been established. lamotrigine extended-release is contraindicated in patients who have demonstrated hypersensitivity (e.g., rash, angioedema, acute urticaria, extensive pruritus, mucosal ulceration) to the drug or its ingredients [see boxed warning, warnings and precautions ( 5.1, 5.2)] . as w

Israele - inglese - Ministry of Health

teva israel ltd - rasagiline as mesylate - tablets - rasagiline as mesylate 1 mg - rasagiline - rasagiline - azilect is indicated for the treatment of idiopathic parkinson's disease (pd) as monotherapy (without levodopa)or as adjunct therapy (with levodopa) in patients with end of dose fluctuations.

Israele - inglese - Ministry of Health

teva pharmaceutical industries ltd, israel - rasagiline as mesylate - tablets - rasagiline as mesylate 1 mg - rasagiline - rasagiline - azilect is indicated for the treatment of idiopathic parkinson's disease (pd) as monotherapy (without levodopa)or as adjunct therapy (with levodopa) in patients with end of dose fluctuations.